<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126802</url>
  </required_header>
  <id_info>
    <org_study_id>GU-06-0052/ethics 21781</org_study_id>
    <nct_id>NCT00126802</nct_id>
  </id_info>
  <brief_title>The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer</brief_title>
  <official_title>The Role of Tomotherapy (Dynamic IMRT and Megavoltage CT Scanning) in Hypofractionated/Dose Escalated Conformal Radiation Treatment Using Magnetic Resonance Spectroscopy (MRS) Scans to Predict and Document the Pattern of Local Failure for High Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helical tomotherapy is being used to treat the prostate gland, local rates of spread and
      regional lymph nodes whilst sparing gross structures. The radiation to the gross disease in
      the prostate is hypofractionated and dose escalated. Magnetic resonance spectroscopic imaging
      (MRSI) is incorporated into pre- and post-treatment evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rectal Toxicity</measure>
    <time_frame>5 weeks</time_frame>
    <description>Determine the acute and late rectal toxicity of high-dose short-course hypofractionated radiotherapy in five weeks in the treatment of high rish prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prostate-specific antigen (PSA) and MRSI disease control</measure>
    <time_frame>3 years</time_frame>
    <description>Determine the biochemical control (freedom from PSA failure) rate, overall and disease free survival.</description>
  </secondary_outcome>
  <enrollment type="Actual">60</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tomotherapy</intervention_name>
    <description>Standard 45 Gy in 25 fractions in 5 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk localized prostate cancer

        Exclusion Criteria:

          -  Low/intermediate risk, metastatic cancer

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Pearcey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <last_update_submitted>July 4, 2016</last_update_submitted>
  <last_update_submitted_qc>July 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tomotherapy</keyword>
  <keyword>MRSZ</keyword>
  <keyword>high risk prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

